Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $5.00. The company’s shares closed yesterday at $1.49. El ...

After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Investing.com - Leerink Partners has lowered its price target on iTeos Therapeutics (NASDAQ: ITOS) to $10.00 from $12.00 while maintaining a Market Perform rating on the stock.

On behalf of iTeos shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and ...

Concentra is living up to its reputation of buying battered biotechs, swooping in to grab iTeos after the failure of its GSK-partnered TIGIT drug.

While we acknowledge the potential of iTeos Therapeutics, Inc. (NASDAQ:ITOS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns ...

Today's biotech news includes more biopharma trials happening only in China, Merck and Daiichi Sankyo withdrawing an FDA application, etc.

Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the ...